No products in the cart.
Lenalidomide Capsules (Qipuyi) – 25mg
$1.00
Lenalidomide (brand name Qipuyi) is an immunomodulatory drug (IMiD) produced by Qilu Pharmaceutical Co., Ltd. Each box contains 21 capsules of 25mg each. Approved by China’s NMPA under H20193115, and product code 86904021003685 (barcodes: 6915798005257, 6915798005721). Strictly for laboratory research use only
Description
Lenalidomide Capsules Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Lenalidomide Capsules (Qipuyi) |
| Strength | 25mg per capsule |
| Pack Size | 21 capsules per box |
| Formulation | Oral capsule |
| Approval No. | China NMPA H20193115 |
| Product Code | 86904021003685 |
| Barcodes | 6915798005257, 6915798005721 |
| Manufacturer | Qilu Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only—Not for human use |
Overview & Mechanism of Action
Lenalidomide is an oral immunomodulatory agent that modulates the E3 ubiquitin ligase complex and inhibits tumor cell growth. It is approved for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma dailymed.nlm.nih.gov+3en.wikipedia.org+3aetna.com+3.
Clinical Dose Reference (For Research Context)
Multiple Myeloma: 25mg daily on Days1–21 of a 28-day cycle aetna.com+4dailymed.nlm.nih.gov+4accessdata.fda.gov+4.
Myelodysplastic Syndrome: 10mg daily, adjusted for blood counts.
Lymphomas: 20–25mg daily on 21/28-day cycles combined with rituximab
Research Applications
Ideal for:
IMiD-related biochemical and cellular studies
Multiple myeloma and lymphoma laboratory models
Pharmacokinetic/pharmacodynamic profiling
Immune modulation and tumor biology research
Handling & Storage
Storage: Store at 20–25°C, protect from moisture
Handling: Use standard lab PPE; prevent ingestion or contact
Packaging: Capsules in blister packaging – verify seal before use
Lenalidomide Capsules References
Qilu listing and manufacturing details
FDA label and dosing schedules
Clinical approvals in China and licensed uses
Mechanism and hematologic research applications
Additional information
| Weight | 1.1 kg |
|---|---|
| Dimensions | 18 × 16 × 18 cm |
Related products
Pirtobrutinib Tablets
Pirtobrutinib Tablets (brand name: Jaypirca) is the world’s first non-covalent BTK inhibitor, provided here as 100?mg oral film?coated tablets. Manufactured by Lilly del Caribe, Inc. and approved for import in China (NMPA No. HJ20240116; code 86978403001613). Supplied with clear indication for research/investigational use only, not for human therapeutic use. $2.00Reduced Glutathione Injection
Ruiyang Reduced Glutathione Injection (0.6g per vial × 10) by Ruiyang Pharmaceutical Co., Ltd. Ideal for antioxidant, detoxification, and hepatic-protection research in metabolic and oxidative stress studies. $2.00Toremifene Citrate Tablets
Toremifene citrate (brand name Ovry), manufactured by Jiangsu Ascend Pharmaceutical Co., Ltd., is a selective estrogen receptor modulator (SERM) approved in China (NMPA No.H20243050, code?86901425001187). Each box contains 30 tablets (60mg each) in 3 blister cards (barcode 6953272600284). Strictly for laboratory research purposes only. $1.00Irinotecan Hydrochloride Liposome Injection
Irinotecan Hydrochloride Liposome Injection Du’EnYi® is China’s first domestically approved liposome-encapsulated irinotecan injection, equivalent to ONIVYDE®. Each 10mL vial contains 43mg irinotecan and is strictly for laboratory research use only—not for clinical or human application.Please consult the staff for other purposes. $1.00
Reviews
There are no reviews yet.